Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of sepsis modulated circulating microRNAs.
Szilágyi B, Fejes Z, Pócsi M, Kappelmayer J, Nagy B Jr. Szilágyi B, et al. EJIFCC. 2019 Jun 24;30(2):128-145. eCollection 2019 Jun. EJIFCC. 2019. PMID: 31263389 Free PMC article. Review.
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
Lebwohl M, Merola JF, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb AB. Lebwohl M, et al. Among authors: szilagyi b. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00568-1. doi: 10.1016/j.jaad.2024.03.041. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38588819 Free article.
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
Strober B, Tada Y, Mrowietz U, Lebwohl M, Foley P, Langley RG, Warren RB, Wang M, Vanvoorden V, Szilagyi B, Ciaravino V, Paul C. Strober B, et al. Among authors: szilagyi b. Br J Dermatol. 2023 May 24;188(6):749-759. doi: 10.1093/bjd/ljad035. Br J Dermatol. 2023. PMID: 36967713 Clinical Trial.
81 results